Cordlife (SGX:P8A) expects to book a loss for the year ended Dec. 31, 2024, according to a filing with the Singapore Exchange on Tuesday.
The company has attributed this to suspension of Singapore operations and ban on collection, testing, processing of new cord blood and human tissues and conditional resumption of operatins in a controlled manner.
The company expects revenue to improve during 2025 and will release its financial results on or before March 1.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.